CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade FibroGen, Inc - FGEN CFD

17.79
3.55%
0.23
Low: 17.36
High: 18.71
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.23
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

FibroGen Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 17.18
Open* 18.65
1-Year Change* 94.88%
Day's Range* 17.36 - 18.71
52 wk Range 8.67-25.69
Average Volume (10 days) 883.63K
Average Volume (3 months) 18.38M
Market Cap 1.69B
P/E Ratio -100.00K
Shares Outstanding 97.58M
Revenue 116.07M
EPS -3.27
Dividend (Yield %) N/A
Beta 0.79
Next Earnings Date Aug 7, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 2, 2023 17.79 -0.94 -5.02% 18.73 19.05 17.34
Jun 1, 2023 17.18 0.22 1.30% 16.96 17.59 16.70
May 31, 2023 17.16 0.15 0.88% 17.01 17.61 16.72
May 30, 2023 17.04 0.47 2.84% 16.57 17.33 16.46
May 26, 2023 16.65 0.03 0.18% 16.62 16.80 16.33
May 25, 2023 16.82 0.16 0.96% 16.66 16.91 16.44
May 24, 2023 16.90 -0.05 -0.29% 16.95 17.33 16.51
May 23, 2023 17.27 0.06 0.35% 17.21 18.03 16.99
May 22, 2023 17.16 -0.14 -0.81% 17.30 18.02 16.96
May 19, 2023 17.49 -0.07 -0.40% 17.56 18.07 17.20
May 18, 2023 17.53 0.01 0.06% 17.52 17.89 17.29
May 17, 2023 17.77 0.80 4.71% 16.97 17.86 16.92
May 16, 2023 17.40 0.25 1.46% 17.15 17.51 17.08
May 15, 2023 17.58 0.46 2.69% 17.12 17.91 17.03
May 12, 2023 17.31 -0.11 -0.63% 17.42 17.66 17.09
May 11, 2023 17.48 -0.12 -0.68% 17.60 18.00 17.38
May 10, 2023 17.65 0.25 1.44% 17.40 17.84 17.17
May 9, 2023 17.30 1.25 7.79% 16.05 17.89 15.97
May 8, 2023 17.61 0.58 3.41% 17.03 17.73 16.55
May 5, 2023 17.29 1.14 7.06% 16.15 17.55 15.83

FibroGen, Inc Events

Time (UTC) Country Event
Wednesday, June 7, 2023

Time (UTC)

15:00

Country

US

Event

FibroGen Inc Annual Shareholders Meeting
FibroGen Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Friday, June 16, 2023

Time (UTC)

15:00

Country

US

Event

FibroGen Inc Annual Shareholders Meeting
FibroGen Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, August 7, 2023

Time (UTC)

10:59

Country

US

Event

Q2 2023 FibroGen Inc Earnings Release
Q2 2023 FibroGen Inc Earnings Release

Forecast

-

Previous

-
Monday, November 6, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 FibroGen Inc Earnings Release
Q3 2023 FibroGen Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 140.734 235.309 176.319 256.577 212.958
Revenue 140.734 235.309 176.319 256.577 212.958
Total Operating Expense 441.759 523.839 368.199 345.891 299.651
Selling/General/Admin. Expenses, Total 127.474 120.557 97.238 126.557 63.812
Research & Development 296.791 387.043 252.924 209.265 235.839
Operating Income -301.025 -288.53 -191.88 -89.314 -86.693
Interest Income (Expense), Net Non-Operating 6.156 -2.153 3.151 12.672 0.577
Net Income Before Taxes -294.869 -290.683 -188.729 -76.642 -86.116
Net Income After Taxes -295.227 -291.03 -189.089 -76.97 -86.42
Net Income Before Extra. Items -293.654 -290.023 -189.291 -76.97 -86.42
Net Income -293.654 -290.023 -189.291 -76.97 -86.42
Income Available to Common Excl. Extra. Items -293.654 -290.023 -189.291 -76.97 -86.42
Income Available to Common Incl. Extra. Items -293.654 -290.023 -189.291 -76.97 -86.42
Diluted Net Income -293.654 -290.023 -189.291 -76.97 -86.42
Diluted Weighted Average Shares 93.582 92.349 89.854 86.633 84.062
Diluted EPS Excluding Extraordinary Items -3.13793 -3.14051 -2.10665 -0.88846 -1.02805
Diluted Normalized EPS -3.13793 -3.14051 -2.10665 -0.88846 -1.02805
Total Extraordinary Items
Cost of Revenue, Total 20.28 12.871 8.869 1.147
Gross Profit 120.454 222.438 167.45 255.43
Depreciation / Amortization 0.587 4.639 10.369 10.307
Other Operating Expenses, Total -3.373 -1.271 -1.201 -1.385
Equity In Affiliates 1.573 1.007 -0.202
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 36.161 34.367 15.735 29.806 60.827
Revenue 36.161 34.367 15.735 29.806 60.827
Cost of Revenue, Total 3.491 4.925 4.308 6.809 4.238
Gross Profit 32.67 29.442 11.427 22.997 56.589
Total Operating Expense 112.252 100.519 109.392 108.03 123.82
Selling/General/Admin. Expenses, Total 34.275 33.966 29.902 30.258 30.564
Research & Development 74.486 61.628 75.182 70.963 89.018
Other Operating Expenses, Total
Operating Income -76.091 -66.152 -93.657 -78.224 -62.993
Interest Income (Expense), Net Non-Operating -1.336 -0.195 1.714 5.058 -0.419
Net Income Before Taxes -77.427 -66.347 -91.943 -73.166 -63.412
Net Income After Taxes -77.501 -66.455 -92.057 -73.189 -63.525
Equity In Affiliates 0.796 0.28 0.407 0.565 0.32
Net Income Before Extra. Items -76.705 -66.175 -91.65 -72.624 -63.205
Net Income -76.705 -66.175 -91.65 -72.624 -63.205
Income Available to Common Excl. Extra. Items -76.705 -66.175 -91.65 -72.624 -63.205
Income Available to Common Incl. Extra. Items -76.705 -66.175 -91.65 -72.624 -63.205
Diluted Net Income -76.705 -66.175 -91.65 -72.624 -63.205
Diluted Weighted Average Shares 94.691 94.035 93.767 93.475 93.043
Diluted EPS Excluding Extraordinary Items -0.81006 -0.70373 -0.97742 -0.77694 -0.67931
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.81006 -0.70373 -0.97742 -0.77694 -0.67931
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 492.826 474.059 755.11 702.49 690.015
Cash and Short Term Investments 422.008 405.19 686.537 533.757 621.402
Cash 135.819 111.422 88.046 40.715 38.783
Cash & Equivalents 19.881 59.801 590.347 85.551 50.475
Short Term Investments 266.308 233.967 8.144 407.491 532.144
Total Receivables, Net 16.299 25.401 41.883 153.665 63.684
Accounts Receivable - Trade, Net 28.387 36.331 46.01 158.51 16.474
Prepaid Expenses 9.73 7.383 8.353 6.464 4.929
Total Assets 610.087 773.821 826.84 857.397 880.598
Property/Plant/Equipment, Total - Net 100.933 120.15 65.296 84.276 127.198
Property/Plant/Equipment, Total - Gross 253.644 252.362 199.305 195.752 192.397
Accumulated Depreciation, Total -152.711 -132.212 -134.009 -111.476 -65.199
Long Term Investments 9.409 171.621 2.972 61.118 55.82
Other Long Term Assets, Total 6.919 7.991 3.462 9.513 7.565
Total Current Liabilities 273.562 225.497 163.187 102.745 89.033
Accounts Payable 30.758 26.097 24.789 6.088 9.139
Accrued Expenses 229.639 180.356 104.384 83.816 66.123
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 13.129 19.033 21.684 0.49 13.771
Total Liabilities 631.534 564.675 404.662 341.262 371.399
Total Long Term Debt 17.054 17.616 44.088 55.531 113.955
Long Term Debt 16.917 17.613 18.697 16.78 16.798
Capital Lease Obligations 0.137 0.003 25.391 38.751 97.157
Minority Interest 19.967 19.967 19.271 19.271 19.271
Other Liabilities, Total 320.951 292.403 169.441 163.715 149.14
Total Equity -21.447 209.146 422.178 516.135 509.199
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.942 0.929 0.914 0.877 0.854
Additional Paid-In Capital 1541.02 1476.41 1399.77 1300.72 1226.45
Retained Earnings (Accumulated Deficit) -1557.69 -1264.03 -974.011 -784.72 -715.827
Other Equity, Total -5.72 -4.163 -4.499 -0.747 -2.281
Total Liabilities & Shareholders’ Equity 610.087 773.821 826.84 857.397 880.598
Total Common Shares Outstanding 94.1661 92.881 91.441 87.657 85.432
Total Inventory 40.436 31.015 16.53 6.887
Other Current Assets, Total 4.353 5.07 1.807 1.717
Current Port. of LT Debt/Capital Leases 0.036 0.011 12.33 12.351
Deferred Income Tax 9.192 8.675
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 430.549 492.826 474.224 520.643 524.415
Cash and Short Term Investments 355.949 422.008 408.52 438.133 428.075
Cash 145.81 135.819 104.509 128.152 165.436
Cash & Equivalents 42.74 19.881 51.451 39.606 20.46
Short Term Investments 167.399 266.308 252.56 270.375 242.179
Total Receivables, Net 17.654 16.299 15.328 33.573 43.883
Accounts Receivable - Trade, Net 29.217 28.387 29.665 60.352 82.638
Total Inventory 42.456 40.436 39.95 40.899 43.067
Prepaid Expenses 14.49 9.73 10.426 8.038 9.39
Other Current Assets, Total 4.353
Total Assets 538.544 610.087 608.837 686.789 745.934
Property/Plant/Equipment, Total - Net 95.367 100.933 105.19 109.159 114.871
Property/Plant/Equipment, Total - Gross 253.644
Accumulated Depreciation, Total -152.711
Long Term Investments 5.884 9.409 22.411 50.414 97.643
Other Long Term Assets, Total 6.744 6.919 7.012 6.573 9.005
Total Current Liabilities 254.746 273.562 251.994 240.34 255.374
Accounts Payable 71.282 30.758 19.323 29.36 36.353
Accrued Expenses 166.969 229.639 224.577 202.681 211.518
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.036
Other Current Liabilities, Total 16.495 13.129 8.094 8.299 7.503
Total Liabilities 587.396 631.534 582.531 583.009 587.886
Total Long Term Debt 17.276 17.054 15.422 16.439 17.374
Long Term Debt 17.276 16.917 15.422 16.439 17.374
Capital Lease Obligations 0.137
Deferred Income Tax
Minority Interest 19.967 19.967 19.967 19.967 19.967
Other Liabilities, Total 295.407 320.951 295.148 306.263 295.171
Total Equity -48.852 -21.447 26.306 103.78 158.048
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.966 0.942 0.939 0.937 0.933
Additional Paid-In Capital 1589.15 1541.02 1524.23 1509.64 1490.86
Retained Earnings (Accumulated Deficit) -1634.39 -1557.69 -1491.51 -1399.86 -1327.24
Other Equity, Total -4.57 -5.72 -7.346 -6.93 -6.505
Total Liabilities & Shareholders’ Equity 538.544 610.087 608.837 686.789 745.934
Total Common Shares Outstanding 96.623 94.1661 93.936 93.733 93.289
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -293.654 -290.023 -189.291 -76.97 -86.42
Cash From Operating Activities -145.933 -82.232 81.602 -78.705 -76.144
Cash From Operating Activities 10.604 14.809 22.047 21.454 6.562
Non-Cash Items 66.687 132.899 74.216 62.47 52.112
Cash Interest Paid 0.104 0.094 0.135 0.174 0.218
Changes in Working Capital 70.43 60.083 174.63 -85.659 -48.398
Cash From Investing Activities 89.116 -426.972 452.487 120.018 -522.123
Capital Expenditures -38.741 -30.186 -3.994 -5.762 -8.02
Other Investing Cash Flow Items, Total 127.857 -396.786 456.481 125.78 -514.103
Cash From Financing Activities 46.776 -0.563 13.343 -4.3 13.875
Financing Cash Flow Items -6.62 -7.372 -11.463 -12.75 -15.612
Issuance (Retirement) of Stock, Net 53.934 12.701 37.829 20.778 29.847
Issuance (Retirement) of Debt, Net -0.538 -5.892 -13.023 -12.328 -0.36
Foreign Exchange Effects -5.482 2.597 4.695 -0.005 -0.008
Net Change in Cash -15.523 -507.17 552.127 37.008 -584.4
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -76.705 -293.654 -227.479 -135.829 -63.205
Cash From Operating Activities -101.591 -145.933 -93.42 -41.54 -8.476
Cash From Operating Activities 2.965 10.604 7.914 5.235 2.584
Non-Cash Items 18.148 66.687 49.928 34.441 17.77
Changes in Working Capital -45.999 70.43 76.217 54.613 34.375
Cash From Investing Activities 103.482 89.116 88.023 43.24 25.935
Capital Expenditures -0.591 -38.741 -38.408 -37.543 -36.638
Other Investing Cash Flow Items, Total 104.073 127.857 126.431 80.783 62.573
Cash From Financing Activities 31.485 46.776 -1.898 -0.806 -2.893
Financing Cash Flow Items 0 -6.62 -4.562 -3.361 -2.974
Issuance (Retirement) of Stock, Net 31.657 53.934 2.989 2.779 0.183
Issuance (Retirement) of Debt, Net -0.172 -0.538 -0.325 -0.224 -0.102
Foreign Exchange Effects -0.526 -5.482 -7.968 -4.359 0.107
Net Change in Cash 32.85 -15.523 -15.263 -3.465 14.673
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
PRIMECAP Management Company Investment Advisor 14.4767 14126697 231619 2023-03-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.0286 8810326 -613439 2023-03-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.2737 6122003 89685 2023-03-31 LOW
Astellas Pharma Inc Corporation 5.0915 4968367 0 2023-01-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.1772 4076167 -188810 2023-03-31 LOW
Point72 Asset Management, L.P. Hedge Fund 3.5113 3426427 -1355218 2023-03-31 HIGH
First Trust Advisors L.P. Investment Advisor 2.7884 2720975 -254678 2023-03-31 LOW
Baker Bros. Advisors LP Hedge Fund 2.7027 2637384 1262173 2023-03-31 LOW
Armistice Capital LLC Hedge Fund 2.3693 2312000 -1552000 2023-03-31 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7703 1727545 70450 2023-03-31 LOW
Two Sigma Investments, LP Hedge Fund 1.7676 1724909 512435 2023-03-31 HIGH
Schroder Investment Management North America Inc. Investment Advisor 1.5138 1477161 -246616 2023-03-31 LOW
Artisan Partners Limited Partnership Investment Advisor 1.3847 1351230 1351230 2023-03-31 LOW
Assenagon Asset Management S.A. Investment Advisor 1.3779 1344583 1344583 2023-03-31 HIGH
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.1877 1159027 -348288 2023-03-31 MED
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 1.1157 1088768 593915 2023-03-31 LOW
Eventide Asset Management, LLC Investment Advisor 0.9838 960000 960000 2023-03-31 MED
Nuveen LLC Pension Fund 0.9185 896293 328958 2023-03-31 LOW
Adage Capital Management, L.P. Hedge Fund 0.8711 850000 -1800000 2023-03-31 LOW
Eagle Asset Management, Inc. Investment Advisor/Hedge Fund 0.8488 828307 -74825 2023-03-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

535K+

Traders

87K+

Active clients monthly

$113M+

Monthly investing volume

$64M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

FibroGen, Inc Company profile

About FibroGen Inc

FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.

Industry: Biotechnology & Medical Research (NEC)

409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US

Income Statement

  • Annual
  • Quarterly

People also watch

XRP/USD

0.52 Price
-0.750% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00446

Oil - Crude

71.98 Price
+2.450% 1D Chg, %
Long position overnight fee -0.0201%
Short position overnight fee -0.0018%
Overnight fee time 21:00 (UTC)
Spread 0.04

US100

14,557.80 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 3.0

Gold

1,948.36 Price
-1.480% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading